Skip to content

S. Thompson

3 papers in the library · 1,761 citations · publishing 2016-2022

Papers

Sort Most recent Most cited

Experimenters’ sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor

Nature Neuroscience August 30, 2022 Polymnia Georgiou, Panos Zanos, Ta-Chung M. Mou et al.

We show that the sex of human experimenters affects mouse behaviors and responses following administration of the rapid-acting antidepressant ketamine and its bioactive metabolite (2R,6R)-hydroxynorketamine. Mice showed aversion to the scent of male experimenters, preference for the scent of female experimenters and increased stress susceptibility when handled by male experimenters. This...

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function

Proceedings of the National Academy of Sciences February 22, 2019 E. Lumsden, Timothy A. Troppoli, S. J. Myers et al. 159 citations

Significance Standard antidepressant treatments require weeks to show effectiveness. A single subanesthetic dose of ketamine rapidly attenuates many clinical signs and symptoms of depression; however, ketamine treatment also has many adverse effects, including dissociation and potential for abuse, which are mediated by NMDA glutamate receptor (NMDAR) inhibition. Previous work has revealed that...

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Nature April 24, 2016 Panos Zanos, Ruin Moaddel, Patrick J. Morris et al. 1,602 citations

Major depressive disorder affects around 16 per cent of the world population at some point in their lives. Despite the availability of numerous monoaminergic-based antidepressants, most patients require several weeks, if not months, to respond to these treatments, and many patients never attain sustained remission of their symptoms. The non-competitive, glutamatergic NMDAR (N-methyl-d-aspartate...